Yu Kono1, Taichi Wakabayashi2, Masahisa Kobayashi3, Toya Ohashi2, Yoshikatsu Eto4, Hiroyuki Ida2, Yasuyuki Iguchi5. 1. Department of Neurology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. Electronic address: yu1028@jikei.ac.jp. 2. Department of Pediatrics, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan; Division of Gene Therapy, Research Center for Medical Sciences, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. 3. Department of Pediatrics, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. 4. Advanced Clinical Research Center, Institute of Neurological Disorders, Kanagawa, Japan. 5. Department of Neurology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
Abstract
BACKGROUND AND PURPOSE: Fabry disease (FD) is an X-linked lysosomal storage disorder frequently associated with the central nervous system manifestations. Although white matter hyperintensity (WMH) on MRI has been previously reported, little is known about cerebral microbleeds (CMBs) in patients with FD. Our aim is to investigate the clinical characteristics of CMBs in patients with FD. METHODS: All patients with FD were diagnosed by enzyme activity and/or gene analysis at Jikei University Hospital. We retrospectively enrolled consecutive patients with FD who underwent MRI study, including fluid-attenuated inversion recovery and susceptibility-weighted imaging, between July 2008 and September 2013. After categorizing the patients into CMB-positive and CMB-negative groups, we compared the clinical characteristics between the 2 groups. RESULTS: We enrolled 54 patients (males, 24; median age 39 years, interquartile range; 29-50 years). The CMB-positive group included 16 (30%) patients. The number of males was significantly higher in the CMB-positive group than in the CMB-negative group (75% versus 32%, P = .003). The prevalence rates of chronic kidney disease (CKD) (estimated glomerular filtration rate < 60 mL/min/1.73 m(2)) and WMH were higher in the CMB-positive group than in the CMB-negative group (CKD: 44% versus 13%, P = .013; WMH: 88% versus 58%, P = .035). No significant differences in the number of vascular risk factors were observed between the 2 groups. CONCLUSIONS: The distinct characteristics of FD patients with CMBs were male sex, presence of CKD, and WMH. These factors may play an important role in the mechanism of hemorrhagic stroke in FD.
BACKGROUND AND PURPOSE:Fabry disease (FD) is an X-linked lysosomal storage disorder frequently associated with the central nervous system manifestations. Although white matter hyperintensity (WMH) on MRI has been previously reported, little is known about cerebral microbleeds (CMBs) in patients with FD. Our aim is to investigate the clinical characteristics of CMBs in patients with FD. METHODS: All patients with FD were diagnosed by enzyme activity and/or gene analysis at Jikei University Hospital. We retrospectively enrolled consecutive patients with FD who underwent MRI study, including fluid-attenuated inversion recovery and susceptibility-weighted imaging, between July 2008 and September 2013. After categorizing the patients into CMB-positive and CMB-negative groups, we compared the clinical characteristics between the 2 groups. RESULTS: We enrolled 54 patients (males, 24; median age 39 years, interquartile range; 29-50 years). The CMB-positive group included 16 (30%) patients. The number of males was significantly higher in the CMB-positive group than in the CMB-negative group (75% versus 32%, P = .003). The prevalence rates of chronic kidney disease (CKD) (estimated glomerular filtration rate < 60 mL/min/1.73 m(2)) and WMH were higher in the CMB-positive group than in the CMB-negative group (CKD: 44% versus 13%, P = .013; WMH: 88% versus 58%, P = .035). No significant differences in the number of vascular risk factors were observed between the 2 groups. CONCLUSIONS: The distinct characteristics of FDpatients with CMBs were male sex, presence of CKD, and WMH. These factors may play an important role in the mechanism of hemorrhagic stroke in FD.
Authors: D Lyndon; I Davagnanam; D Wilson; F Jichi; A Merwick; F Bolsover; H R Jager; L Cipolotti; C Wheeler-Kingshott; D Hughes; E Murphy; R Lachmann; D J Werring Journal: J Neurol Date: 2020-10-19 Impact factor: 4.849
Authors: James D Stefaniak; Laura M Parkes; Adrian R Parry-Jones; Gillian M Potter; Andy Vail; Ana Jovanovic; Craig J Smith Journal: Neurology Date: 2018-09-12 Impact factor: 9.910